LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Mirati Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi

By Trading Economics

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

-0.05% downside

Ziņu noskaņojums

By Acuity

8%

92%

6 / 380 Rangs Healthcare

Mirati Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. jūn. 20:51 UTC

Peļņas

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 20:48 UTC

Tirgus saruna

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025. g. 27. jūn. 19:31 UTC

Tirgus saruna

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025. g. 27. jūn. 19:19 UTC

Tirgus saruna

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025. g. 27. jūn. 19:16 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025. g. 27. jūn. 18:39 UTC

Tirgus saruna
Peļņas

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025. g. 27. jūn. 18:29 UTC

Tirgus saruna

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:18 UTC

Tirgus saruna

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:16 UTC

Tirgus saruna

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025. g. 27. jūn. 17:16 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025. g. 27. jūn. 17:08 UTC

Peļņas

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025. g. 27. jūn. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025. g. 27. jūn. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 27. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 27. jūn. 15:59 UTC

Tirgus saruna

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025. g. 27. jūn. 15:56 UTC

Tirgus saruna

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Mirati Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

-0.05% uz leju

Prognoze 12 mēnešiem

Vidējais 58.67 USD  -0.05%

Augstākais 59 USD

Zemākais 58 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Mirati Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

0

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

6 / 380 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

EBITDA

Pamatdarbības peļņa

$

Par Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.